Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 17 of 27
A Study of LY2484595 on the Electrical Activity of the Heart
NCT01537887
Effect of Teriparatide on Hip Fracture Healing
NCT01473589
A Study of LY3009104 in Healthy Participants
NCT01536951
A Study of LY2886721 in Healthy Participants
NCT01534273
Second Study of the Effect of Teriparatide on Hip Fracture Healing
NCT01473602
A Study in Participants With Type I Diabetes Mellitus
NCT01454284
A Study in Participants With Type 1 Diabetes Mellitus
NCT01481779
On Open-Label Study in Participants With Systemic Lupus Erythematosus
NCT01488708
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
NCT01490632
A Study of LY3007113 in Participants With Advanced Cancer
NCT01463631
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
NCT01474538
A Study in Participants With Type 2 Diabetes Mellitus
NCT01468987
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
NCT01505530
A Long-Term Study in Schizophrenia
NCT01487083
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease
NCT01476696
A Study in Patients With Type 2 Diabetes Mellitus
NCT01435616
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer
NCT01427933
A Study of LY3031207 in Healthy Subjects
NCT01449630
A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart
NCT01460368
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
NCT01448824
A Study of LY2484595 in Healthy Subjects
NCT01450098
A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants
NCT01458210
A Study to Evaluate the Effect of Clarithromycin on LY2216684
NCT01460407
A Study to Evaluate the Effect of Genotype on LY2216684
NCT01460381
A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
NCT01426412
A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants
NCT01436201
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
NCT01439568
A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet
NCT01430091
A Study in Adults With Type 2 Diabetes
NCT01421459
A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants
NCT01432938
A Study in Adults With Type 1 Diabetes
NCT01421147
A Study of LY2523355 in Participants With Breast Cancer
NCT01416389
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
NCT01408888
A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels
NCT01419236
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
NCT01391130
A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors
NCT01316263
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
NCT01394952
A Study to Evaluate the Effect of Food on LY2216684
NCT01389765
A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects
NCT01389752
A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement
NCT01369511
A Bioavailability Study of LY2452473 and Tadalafil
NCT01401543
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
NCT01400971
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
NCT01346358
A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer
NCT01373164
A Study of LY2216684 in Healthy Females
NCT01373931
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
NCT01358968
A Study in Pediatric Participants With Generalized Anxiety Disorder
NCT01226511
Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants
NCT01367262
A Study of LY2216684 in Healthy Participants
NCT01380691
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.